Literature DB >> 10223589

The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility.

A P MacGowan1, M Wootton, H A Holt.   

Abstract

Ciprofloxacin has a four-fold greater in-vitro activity than levofloxacin against Pseudomonas aeruginosa, but levofloxacin has a four-fold higher area under the serum concentration-time curve (AUC) for an equivalent dose. It has been proposed that the AUC/MIC ratio is a general predictor of antibacterial efficacy for quinolones. Using an in-vitro kill curve technique, performed in quadruplicate, with nine antibiotic concentrations and three strains of P. aeruginosa with varying quinolone susceptibility, we constructed sigmoidal dose-response curves for AUC(0-6.5)/MIC and area under the bacterial kill curve (AUBKC) or AUC(0-24)/MIC and log change in viable count at 24 h (delta24). For levofloxacin the log AUC(0-6.5)/MIC ratio to produce 50% of the maximal effect was 0.74 +/- 0.13 (r2 = 0.9435) for levofloxacin and 0.82 +/- 0.06 (r2 = 0.7935) for ciprofloxacin. The log AUC(0-24)/MIC ratio to produce 50% maximal effect was 1.58 +/- 0.13 (r2 = 0.7788) for levofloxacin and 1.37 +/- 0.12 (r2 = 0.7207) for ciprofloxacin. An AUC(0-24)/MIC ratio of 125 produced 85.4% of the maximal response with levofloxacin and 81.5% with ciprofloxacin. These data suggest that levofloxacin and ciprofloxacin have equivalent activity against P. aeruginosa at equivalent AUC/MIC ratios.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10223589     DOI: 10.1093/jac/43.3.345

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Impact of a fluoroquinolone formulary change on acquisition of quinolone-resistant gram-negative bacilli.

Authors:  B N Hota; S Pur; L Phillips; R A Weinstein; J Segreti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-06       Impact factor: 3.267

2.  Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study.

Authors:  G Samonis; E Koutsounaki; D E Karageorgopoulos; P Mitsikostas; C Kalpadaki; V Bozionelou; I Bompolaki; J Sgouros; V Taktikou; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-31       Impact factor: 3.267

Review 3.  A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.

Authors:  S J Martin; R Jung; C G Garvin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

4.  Prevention of febrile neutropenia: use of prophylactic antibiotics.

Authors:  M Cullen; S Baijal
Journal:  Br J Cancer       Date:  2009-09       Impact factor: 7.640

5.  Exploration of the Pharmacodynamics for Pseudomonas aeruginosa Biofilm Eradication by Tobramycin.

Authors:  Devin Sindeldecker; Shaurya Prakash; Paul Stoodley
Journal:  Antimicrob Agents Chemother       Date:  2021-10-25       Impact factor: 5.938

Review 6.  Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.

Authors:  Wael E Shams; Martin E Evans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Quinolone antibiotics.

Authors:  Thu D M Pham; Zyta M Ziora; Mark A T Blaskovich
Journal:  Medchemcomm       Date:  2019-06-28       Impact factor: 3.597

Review 8.  Should patients with acute exacerbation of chronic bronchitis be treated with antibiotics? Advantages of the use of fluoroquinolones.

Authors:  J Mensa; A Trilla
Journal:  Clin Microbiol Infect       Date:  2006-05       Impact factor: 8.067

9.  Factors influencing fluoroquinolone resistance.

Authors:  Daniel F Sahm; Clyde Thornsberry; Mark E Jones; James A Karlowsky
Journal:  Emerg Infect Dis       Date:  2003-12       Impact factor: 6.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.